WASHINGTON — Today Joanne Duncan is joining the Association for Accessible Medicines as chief operating officer. She will be responsible for leading and managing implementation of a more comprehensive member recruitment strategy. She will drive operational improvement by increasing the alignment between issue prioritization and the budgeting process, maximizing IT functionality and human resources capabilities.
Dan Leonard, longtime leader of the National Pharmaceutical Council who became CEO of the Association for Accessible Medicines in September, discusses the impact of generic medications on health care, and the challenges and opportunities facing the industry. Among the issues addressed are generics’ role in treating COVID-19 patients, the emergence of biosimilars, and the
WASHINGTON — The Association for Accessible Medicines’ president and CEO Dan Leonard issued the following statement on the 2020 election: “The Association for Accessible Medicines looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to safe, effective and affordable generic and biosimilar prescription medicines for all Americans.
The public continues to name health care costs — and prescription drugs in particular — as a top priority. A recent survey from the Kaiser Family Foundation found that eight in 10 Americans say the cost of prescription drugs is unreasonable. At the same time, the value of generic medicines is well established. Consider this:
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
